Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

238 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer.
Herben VM, Panday VR, Richel DJ, Schellens JH, van der Vange N, Rosing H, Beusenberg FD, Hearn S, Doyle E, Beijnen JH, ten Bokkel Huinink WW. Herben VM, et al. Among authors: ten bokkel huinink ww. J Clin Oncol. 1999 Mar;17(3):747-55. doi: 10.1200/JCO.1999.17.3.747. J Clin Oncol. 1999. PMID: 10071262 Clinical Trial.
Urinary and fecal excretion of topotecan in patients with malignant solid tumours.
Herben VM, Schoemaker nE, Rosing H, van Zomeren DM, ten Bokkel Huinink WW, Dubbelman R, Hearn S, Schellens JH, Beijnen JH. Herben VM, et al. Among authors: ten bokkel huinink ww. Cancer Chemother Pharmacol. 2002 Jul;50(1):59-64. doi: 10.1007/s00280-002-0454-2. Epub 2002 Apr 5. Cancer Chemother Pharmacol. 2002. PMID: 12111113 Clinical Trial.
Phase I pharmacokinetic and pharmacodynamic study of Carboplatin and topotecan administered intravenously every 28 days to patients with malignant solid tumors.
Boss DS, Siegel-Lakhai WS, van Egmond-Schoemaker NE, Pluim D, Rosing H, Ten Bokkel Huinink WW, Beijnen JH, Schellens JH. Boss DS, et al. Among authors: ten bokkel huinink ww. Clin Cancer Res. 2009 Jul 1;15(13):4475-83. doi: 10.1158/1078-0432.CCR-08-3144. Epub 2009 Jun 16. Clin Cancer Res. 2009. PMID: 19531625 Clinical Trial.
Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure.
van Warmerdam LJ, Creemers GJ, Rodenhuis S, Rosing H, de Boer-Dennert M, Schellens JH, ten Bokkel Huinink WW, Davies BE, Maes RA, Verweij J, Beijnen JH. van Warmerdam LJ, et al. Among authors: ten bokkel huinink ww. Cancer Chemother Pharmacol. 1996;38(3):254-60. doi: 10.1007/s002800050479. Cancer Chemother Pharmacol. 1996. PMID: 8646800 Clinical Trial.
Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: a European Cancer Centre (ECC) trial.
Huizing MT, Vermorken JB, Rosing H, ten Bokkel Huinink WW, Mandjes I, Pinedo HM, Beijnen JH. Huizing MT, et al. Among authors: ten bokkel huinink ww. Ann Oncol. 1995 Sep;6(7):699-704. doi: 10.1093/oxfordjournals.annonc.a059287. Ann Oncol. 1995. PMID: 8664192 Free article. Clinical Trial.
Clinical pharmacokinetics of topotecan.
Herben VM, ten Bokkel Huinink WW, Beijnen JH. Herben VM, et al. Among authors: ten bokkel huinink ww. Clin Pharmacokinet. 1996 Aug;31(2):85-102. doi: 10.2165/00003088-199631020-00001. Clin Pharmacokinet. 1996. PMID: 8853931 Review.
238 results